References
- European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14(Suppl 5):1–50
- Hörl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14–16: inadequate response to epoetin. Nephrol Dial Transplant 2000;15: 43–50
- Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362–9
- Hörl WH. IV darbepoetin alfa is more effective than IV rHuEPO in maintaining target Hb concentrations in patients with renal anaemia. XXXI EDTNA/ERCA Conference. Abstract booklet XXVIII. 2002;Suppl 1: p. 49\(no. 164)
- Hörl WH, Holzer H, Mayer GJ, et al. Behandlung der renalen Anämie mit Darbepoetin alfa – Ergebnisse einer österreichischen Multicenter-Studie. Wien Klin Wochenschr 2002;114(23–24):967–71
- Schaefer R. Fortschritte bei der Therapie der renalen Anämie: Darbepoetin alfa. Wien Klin Wochenschr 2002;114(23–24):955–7
- The NESP Usage Guidelines Group. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001;16(Suppl 3):22–8
- Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):14–21